Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis.
Balloon-occluded arterial stump pressure
Balloon-occluded transcatheter arterial chemoembolization
Hepatocellular carcinoma
Micro-balloon catheter
Prognosis
Transcatheter arterial chemoembolization
Treatment effect
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
10
2020
accepted:
10
02
2021
pubmed:
13
3
2021
medline:
13
7
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
The aim of this retrospective multicentric study was to compare the tumour response rates of Balloon-occluded Transarterial Chemoembolisation (B-TACE) to non-B-TACE using propensity score matching (PSM) in patients with hepatocellular carcinoma and to investigate the clinical benefit, such as lower rates of TACE re-intervention achieved using B-TACE. The B-TACE procedures (n = 96 patients) were compared with a control group of non-B-TACE treatments (n = 434 pts), performed with conventional (cTACE) or drug-eluting microspheres TACE (DEM-TACE). Data were collected from six European centres from 2015 to 2019. Objective responses (OR) and complete response (CR) rates after the first session and the number of TACE re-interventions were evaluated using PSM (91 patients per arm). The best target OR after PSM were similar for both B-TACE and non-B-TACE (90.1% and 86.8%, p = 0.644); however, CR at 1-6 months was significantly higher for B-TACE (59.3% vs. 41.8%, p = 0.026). Patients treated with B-TACE had a significantly lower retreatment rate during the first 6 months (9.9%% vs. 22.0%, p = 0.041). Post-embolisation syndrome (PES) rates were 8.8% in non-B-TACE and 41.8% in B-TACE (p < 0.001), with no significant differences between groups regarding major adverse events. B-TACE is safe and effective, achieving higher CR rates than non-B-TACE. Patients undergoing B-TACE had a significantly lower retreatment rate within the first 6 months but higher PES rates. Level 3, retrospective study.
Identifiants
pubmed: 33709273
doi: 10.1007/s00270-021-02805-5
pii: 10.1007/s00270-021-02805-5
pmc: PMC8189964
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1048-1059Références
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33(1):41–52. https://doi.org/10.1007/s00270-009-9711-7 .
doi: 10.1007/s00270-009-9711-7
Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64. https://doi.org/10.1038/bjc.2014.199 .
doi: 10.1038/bjc.2014.199
pubmed: 24937669
pmcid: 4102934
Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7. https://doi.org/10.1016/j.dld.2016.02.005 .
doi: 10.1016/j.dld.2016.02.005
pubmed: 26965785
EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019 .
doi: 10.1016/j.jhep.2018.03.019
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/s0140-6736(18)30010-2 .
doi: 10.1016/s0140-6736(18)30010-2
pubmed: 29307467
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.03.50047 .
doi: 10.1002/hep.29913.03.50047
pubmed: 29624699
Iwamoto S, Sanefuji H, Okuda K. Angiographic subsegmentectomy for the treatment of patients with small hepatocellular carcinoma. Cancer. 2003;97(4):1051–6. https://doi.org/10.1002/cncr.11106 .
doi: 10.1002/cncr.11106
pubmed: 12569605
Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188(1):79–83. https://doi.org/10.1148/radiology.188.1.8390073 .
doi: 10.1148/radiology.188.1.8390073
pubmed: 8390073
Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Intl. 2017;11(4):317–70. https://doi.org/10.1007/s12072-017-9799-9 .
doi: 10.1007/s12072-017-9799-9
Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. Liver Cancer. 2020;9(3):245–60. https://doi.org/10.1159/000507370 .
doi: 10.1159/000507370
pubmed: 32647629
pmcid: 7325125
Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9(6):534–40. https://doi.org/10.3348/kjr.2008.9.6.534 .
doi: 10.3348/kjr.2008.9.6.534
pubmed: 19039270
pmcid: 2627241
Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol. 1994;33(Suppl):S84–8. https://doi.org/10.1007/bf00686674 .
doi: 10.1007/bf00686674
pubmed: 8137490
Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365–76. https://doi.org/10.1016/j.jvir.2006.12.004 .
doi: 10.1016/j.jvir.2006.12.004
pubmed: 17377182
Park SH, Cho YK, Ahn YS, Park YO, Kim JK, Chung JW. Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors. Korean J Radiol. 2007;8(2):111–9. https://doi.org/10.3348/kjr.2007.8.2.111 .
doi: 10.3348/kjr.2007.8.2.111
pubmed: 17420628
pmcid: 2626787
Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53(5):1580–9. https://doi.org/10.1002/hep.24246 .
doi: 10.1002/hep.24246
pubmed: 21351114
Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome. J Vasc Interv Radiol. 2016;27(9):1269–78. https://doi.org/10.1016/j.jvir.2016.04.014 .
doi: 10.1016/j.jvir.2016.04.014
pubmed: 27345337
Demachi H, Matsui O, Takashima T. Scanning electron microscopy of intrahepatic microvasculature casts following experimental hepatic artery embolization. Cardiovasc Interv Radiol. 1991;14(3):158. https://doi.org/10.1007/BF02577719 .
doi: 10.1007/BF02577719
Ekataksin W. The isolated artery: an intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers. Hepatology. 2000;31(2):269–79. https://doi.org/10.1002/hep.510310203 .
doi: 10.1002/hep.510310203
pubmed: 10655246
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–17. https://doi.org/10.1016/s0140-6736(03)14964-1 .
doi: 10.1016/s0140-6736(03)14964-1
pubmed: 14667750
Kim BK, Kim SU, Kim KA, Chung YE, Kim MJ, Park MS, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62(6):1304–10. https://doi.org/10.1016/j.jhep.2015.01.022 .
doi: 10.1016/j.jhep.2015.01.022
pubmed: 25637785
Golfieri R, Renzulli M, Mosconi C, Forlani L, Giampalma E, Piscaglia F, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013;24(4):509–17. https://doi.org/10.1016/j.jvir.2012.12.013 .
doi: 10.1016/j.jvir.2012.12.013
pubmed: 23428355
Peck-Radosavljevic M, Kudo M, Raoul J-L, Lee HC, Decaens T, Heo J, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. J Clin Oncol. 2018;36:4018. https://doi.org/10.1200/JCO.2018.36.15_suppl.4018 .
doi: 10.1200/JCO.2018.36.15_suppl.4018
Irie T, Kuramochi M, Takahashi N. Improved accumulation of lipiodol under balloon-occluded transarterial chemoembolization (B-TACE) for hepatocellular carcinoma: measurement of blood pressure at the embolized artery before and after balloon inflation. Jpn J Interv Radiol. 2009;26:49–54. https://doi.org/10.4254/wjh.v10.i7.485 .
doi: 10.4254/wjh.v10.i7.485
Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Interv Radiol. 2013;36(3):706–13. https://doi.org/10.1007/s00270-012-0476-z .
doi: 10.1007/s00270-012-0476-z
Nakamura H, Hashimoto T, Oi H, Sawada S. Iodized oil in the portal vein after arterial embolization. Radiology. 1988;167(2):415–7. https://doi.org/10.1148/radiology.167.2.2833765 .
doi: 10.1148/radiology.167.2.2833765
pubmed: 2833765
Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2015;45(6):663–6. https://doi.org/10.1111/hepr.12403 .
doi: 10.1111/hepr.12403
pubmed: 25132539
Hatanaka T, Arai H, Shibasaki M, Tojima H, Takizawa D, Toyoda M, et al. Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: a retrospective cohort study. Hepatol Res. 2018;48(2):165–75. https://doi.org/10.1111/hepr.12912 .
doi: 10.1111/hepr.12912
pubmed: 28500686
Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial experience with balloon-occluded trans-catheter arterial chemoembolization (b-tace) for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2016;39(3):359–66. https://doi.org/10.1007/s00270-015-1237-6 .
doi: 10.1007/s00270-015-1237-6
Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, et al. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology. 2015;89:27–32. https://doi.org/10.1159/000440628 .
doi: 10.1159/000440628
pubmed: 26584033
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.org/10.1055/s-0030-1247132 .
doi: 10.1055/s-0030-1247132
pubmed: 20175033
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira P. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Interv Radiol. 2017;40(8):1141–6. https://doi.org/10.1007/s00270-017-1703-4 .
doi: 10.1007/s00270-017-1703-4
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 (2017). https://ctep.cancer.gov/protocoldevelopment/electronic applications/docs/CTCAE v5 Quick Reference 8.5x11.pdf
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16. https://doi.org/10.1016/j.jhep.2011.03.007 .
doi: 10.1016/j.jhep.2011.03.007
pubmed: 21703196
Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? a validation study of old and new models. Radiology. 2012;262(2):708–18. https://doi.org/10.1148/radiol.11110282 .
doi: 10.1148/radiol.11110282
pubmed: 22187634
Vincenzi B, Di Maio M, Silletta M, D’Onofrio L, Spoto C, Piccirillo MC, et al. Prognostic relevance of objective response according to easl criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE. 2015;10(7):e0133488. https://doi.org/10.1371/journal.pone.0133488 .
doi: 10.1371/journal.pone.0133488
pubmed: 26230853
pmcid: 4521926
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–16. https://doi.org/10.1002/hep.28453 .
doi: 10.1002/hep.28453
pubmed: 26765068
Trevisani F, Golfieri R. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: where are we now? Hepatology (Baltimore, MD). 2016;64(1):23–5. https://doi.org/10.1002/hep.28554 .
doi: 10.1002/hep.28554
De Baere T, Guiu B, Ronot M, Chevallier P, Sergent G, Tancredi I, et al. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. Cancers (Basel). 2020;12(11):3405. https://doi.org/10.3390/cancers12113405 .
doi: 10.3390/cancers12113405
Aliberti C, Carandina R, Lonardi S, Dadduzio V, Vitale A, Gringeri E, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an italian center. J Vasc Interv Radiol. 2017;28(11):1495–502. https://doi.org/10.1016/j.jvir.2017.07.020 .
doi: 10.1016/j.jvir.2017.07.020
pubmed: 28927662
Veloso Gomes F, Oliveira JA, Correia MT, Costa NV, Abrantes J, Torres D, et al. Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J Vasc Interv Radiol. 2018;29(6):841–9. https://doi.org/10.1016/j.jvir.2018.02.004 .
doi: 10.1016/j.jvir.2018.02.004
pubmed: 29724521
Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE Jr, Gaba RC. Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: contemporary single-center review of clinical outcomes. AJR Am J Roentgenol. 2016;206(3):645–54. https://doi.org/10.2214/AJR.15.14758 .
doi: 10.2214/AJR.15.14758
pubmed: 26901023
Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, et al. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol. 2020;26(3):324–34. https://doi.org/10.3748/wjg.v26.i3.324 .
doi: 10.3748/wjg.v26.i3.324
pubmed: 31988592
pmcid: 6969879
Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, et al. Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the miracle i prospective multicenter study. Cardiovasc Interv Radiol. 2018;41:587–93. https://doi.org/10.1007/s00270-017-1839-2 .
doi: 10.1007/s00270-017-1839-2
Guiu B, Chevallier P, Assenat E, Barbier E, Merle P, Bouvier A, et al. Idarubicin-loaded Beads for chemoembolization of hepatocellular carcinoma: the IDASPHERE II single-arm phase II trial. Radiology. 2019;291:801–8. https://doi.org/10.1148/radiol.2019182399 .
doi: 10.1148/radiol.2019182399
pubmed: 31038408
Guiu B, Colombat S, Piron L, Hermida M, Allimant C, Pierredon-Foulogne MA, et al. Transarterial chemoembolization of hepatocellular carcinoma with idarubicin-loaded tandem drug-eluting embolics. Cancers. 2019;11(7):987. https://doi.org/10.3390/cancers11070987 .
doi: 10.3390/cancers11070987
pmcid: 6678754
Goldman DT, Singh M, Patel RS, Nowakowski FS, Bishay V, Ranade M, et al. Balloon-occluded transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center us preliminary experience. J Vasc Interv Radiol. 2019;30(3):342–6. https://doi.org/10.1016/j.jvir.2018.11.026 .
doi: 10.1016/j.jvir.2018.11.026
pubmed: 30819475
Bucalau AM, Tancredi I, Pezzullo M, Leveque R, Picchia S, Van Laethem JL, Verset G. Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepatic oncol Future Med. 2020. https://doi.org/10.2217/hep-2020-0022 .
doi: 10.2217/hep-2020-0022
Lucatelli P, Ginnani Corradini L, De Rubeis G, Rocco B, Basilico F, Cannavale A, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc Interv Radiol. 2019;42(6):853–62. https://doi.org/10.1007/s00270-019-02192-y .
doi: 10.1007/s00270-019-02192-y
Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2018;10(7):485–95. https://doi.org/10.4254/wjh.v10.i7.485 .
doi: 10.4254/wjh.v10.i7.485
pubmed: 30079135
pmcid: 6068849
Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, et al. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules. Hepatol Res. 2017;47(4):338–46. https://doi.org/10.1111/hepr.12754 .
doi: 10.1111/hepr.12754
pubmed: 27249401
Asayama Y, Nishie A, Ishigami K, Ushijima Y, Takayama Y, Okamoto D, et al. Hemodynamic changes under balloon occlusion of hepatic artery: predictor of the short-term therapeutic effect of balloon-occluded transcatheter arterial chemolipiodolization using miriplatin for hepatocellular carcinoma. Springerplus. 2016;5:157. https://doi.org/10.1186/s40064-016-1880-7 .
doi: 10.1186/s40064-016-1880-7
pubmed: 27026854
pmcid: 4766142
Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol. 2020;30(10):5650–62. https://doi.org/10.1007/s00330-020-06911-9 .
doi: 10.1007/s00330-020-06911-9
pubmed: 32409860
Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy. Cancer Chemother Pharmacol. 1989;23(Suppl):S4-8. https://doi.org/10.1007/BF00647229 .
doi: 10.1007/BF00647229
pubmed: 2466583
Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O’Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl. 2011;17(8):943–54. https://doi.org/10.1002/lt.22314 .
doi: 10.1002/lt.22314
pubmed: 21491582
Miyayama S, Matsui O, Zen Y, Yamashiro M, Hattori Y, Orito N, et al. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: observation on CT during arterial portography. Hepatol Res. 2011;41(9):853–66. https://doi.org/10.1111/j.1872-034X.2011.00836.x .
doi: 10.1111/j.1872-034X.2011.00836.x
pubmed: 21699636
Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, et al. Epirubicin is more effective than Miriplatin in balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Oncology. 2019;96(2):79–86. https://doi.org/10.1159/000492822 .
doi: 10.1159/000492822
pubmed: 30293080
Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatol Res. 2016;46(2):209–14. https://doi.org/10.1111/hepr.12564 .
doi: 10.1111/hepr.12564
pubmed: 26224032
Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results. Hepatol Res. 2016;46(3):E60–9. https://doi.org/10.1111/hepr.12527 .
doi: 10.1111/hepr.12527
pubmed: 25974615
Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, et al. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS ONE. 2014;9(7):e103009. https://doi.org/10.1371/journal.pone.0103009 .
doi: 10.1371/journal.pone.0103009
pubmed: 25047920
pmcid: 4105420
Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, et al. TACE performed in patients with a single nodule of Hepatocellular Carcinoma. BMC Cancer. 2013;14(1):601. https://doi.org/10.1186/1471-2407-14-601 .
doi: 10.1186/1471-2407-14-601